To discover potential therapeutic targets for MM patients, we analyzed MM patient data and identified LILRB1, an immunoreceptor tyrosine-based inhibition motif (ITIM)-containing transmembrane protein which belongs to the leukocyte immunoglobulin‐like receptor (LILR) family3,4, as a promising target for aggressive MM. Here, LILRB1 is linked to Miyoshi myopathy.